Effects of Micronized Trans-resveratrol Treatment on Polycystic Ovary Syndrome (PCOS) Patients

Poznan University of Medical Sciences (PUMS)

Status: Unknown

Conditions: Polycystic Ovary Syndrome (PCOS)

Treatments: Dietary Supplement: Placebo; Dietary Supplement: Micronized trans-resveratrol

Study type: Interventional

Funder types: Other

Identifiers

NCT01720459

681/10

Details and patient eligibility

About

The purpose of this study is to determine whether micronized trans-resveratrol improves clinical (excessive hair, menstrual cycle), endocrine (androgens)and metabolic (lipids, markers of systemic inflammation) in women with polycystic ovary syndrome (PCOS).

Enrollment: 40 estimated patients

Sex: Female

Ages: 18 to 40 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• PCO - Androgen Excess Society criteria: hyperandrogenism (hirsutism) / hyperandrogenemia (testosterone >70ng/dl) and/or oligomenorrhea (<8 spontaneous menses per year) and/or polycystic ovarian morphology on ultrasound
• Normal prolactin, TSH, 17-OH progesterone
• No evidence of androgen producing malignancy, Cushing's syndrome or acromegaly
• Age 18-40

Exclusion criteria

• Use of oral contraceptives and/or other steroid hormones 3 months prior to the study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

40 participants in 2 patient groups, including a placebo group

Micronized trans-resveratrol

Active Comparator group

Description:

Micronized trans-resveratrol

Treatment:

Dietary Supplement: Micronized trans-resveratrol

Placebo

Placebo Comparator group

Treatment:

Dietary Supplement: Placebo